

MASK

MACVIA - ARIA Sentinel Network for allergic rhinitis

Jean Bousquet, Professor, RSCN Co-Chair, MACVIA France Coordinator.
Gabrielle Onorato, MSC Geography, RSCN Secretariat, MACVIA France

Bruxelles, April 5, 2017



European Innovation
Partnership on Active
and Healthy Ageing
REFERENCE SITE





MACVIA France



European Innovation
Partnership on Active
and Healthy Ageing
REFERENCE SITE



Inserm Paris

Labelled in 2016***
Extended to Paris and
Nice

Including the new
« big » region
(Montpellier and
Toulouse)

Métropole de Nice



MASK is focusing on:

- The implementation of multi-sectoral care pathways (rhinitis and asthma, AIRWAYS ICPs, B3 Action Plan)
- Using emerging technologies with real world data
 - App Apple store and Android
 - 6,400 users in 20 countries and 15 languages
 - 2 publications (work productivity and baseline characteristics)
- For individualized and predictive medicine stressing the importance of self-care
- In rhinitis and asthma multimorbidity
- Across the life cycle
- **Transfer of innovation in 25 Reference Sites**



Integrated care pathways for airway diseases (AIRWAYS-ICPs)

European Innovation Partnership on Active and Healthy Ageing, Action Plan B3 (DG Sanco and DG Connect)

Mechanisms of the Development of Allergy (MeDALL, DG Research and Development)
GARD (Global Alliance against Chronic Respiratory Diseases, WHO) research demonstration project

[Bousquet J [1-8], Addis A [6, 7, 9], Adcock I [10], Agache I [4, 11, 12], Agusti A [13, 14], Alonso A [15], Anto JM [3, 13, 16], Bachert C [3, 4, 17, 18], Baena-Cagnani CE [4, 19], Bai C [20, 21], Baigenzhin A [22, 23], Barbara C [24], Barnes PJ [10], Bateman ED [4, 25], Beck L [26], Bedbrook A [2, 4], Bel EH [27], Benezet O [2], Bennoor KS [4, 28], Benson M [29], Bernabeu-Wittel M [6, 30, 31], Bewick M [32], Bindesley-Jensen C [4, 33], Blain H [1, 2, 8], Blasi F [34], Bonini M [4, 35], Bonini S [4, 188], Boulet LP [4, 36], Bourdin A [1, 2, 8, 37], Bourret R [1, 2], Bousquet PJ [4], Brightling CE [38], Briggs A [39], Brozek J [4, 40, 41], Buhl R [42], Bush A [4, 43], Caimmi D [1, 2, 4], Calderon M [44], Calverley P [45], Camargos PA [4, 46], Camuzat T [2], Canonica GW [4, 47], Carlsen KH [3, 4, 48, 49], Casale TB [4], Cazzola M [50], Cepeda Sarabia AM [4, 51, 52], Cesario A [53], Chen YZ [54], Chkhartishvili E [55], Chavannes NH [4, 56, 191], Chiron R [1, 2, 4], Chuchalin A [4, 57, 58], Chung KF [10], Cox L [4, 59], Crooks G [6, 60], Crooks MG [61], Cruz AA [4, 57, 62], Custovic A [4, 5, 63], Dahl R [4, 33], Dahlen SE [189], De Blay F [4, 64, 65], Dedeu T [66], Deleanu D [4, 11, 67], Demoly P [1, 2, 4, 5, 7, 8], Devillier P [4, 68], Didier A [69, 70], Dinh Xuan AT [71], Djukanovic R [72], Dokic D [4, 73], Douagui H [4, 74], Dubakienė R [4, 76, 199], Eglin S [77], Elliot F [6, 196], Emuzyte R [4, 76, 199], Fabbri L [9, 78], Fink Wagner A [79], Fletcher M [57, 80], Fokkens WJ [4, 27, 81], Fonseca J [4, 24, 82, 83], Franco A [84], Frith P [85], Furber A [86], Gaga M [87], Garcés J [6, 88], Garcia-Aymerich J [3, 13, 16], Gamkrelidze A [4, 89], Gonzales-Diaz S [4, 52], Guzmán MA [4, 90], Haahtela T [3, 4, 91, 92], Harrison D [93], Hayot M [1, 2, 8], Heaney LG [94], Heinrich J [3], Hellings PW [4, 5, 95], Hooper J [96], Humbert M [69], Hyland M [97], Iaccarino G [98, 200, 201], Jakovenko D [2], Jardim JR [99], Jeandel C [1, 2, 8], Jenkins C [100], Johnston SL [4, 101], Jonquet O [1, 2, 8], Joos G [17, 102], Kalayci O [4, 5, 103, 104], Karunanithi S [105], Keil T [3, 106, 190], Khaltayev N [4, 57], Kolek V [107], Kowalski ML [108], Kull I [3, 109], Kuna P [4, 7, 57, 110, 111], Kvedariene V [4, 5, 76, 198], Le LT [4, 57, 112], Lodrup Carlsen KC [3, 4, 48, 49], Louis R [113], MacNee W [114], Mair A [115], Majer I [116], Manning P [117], Manuel Keenoy E (de) [6, 118], Masjedi MR [119], Melen E [3, 4, 109], Melo-Gomes E [7, 24], Menzies-Gow A [120], Mercier G [1, 2, 8], Mercier J [1, 2, 7, 8], Michel JP [121], Miculinic N [122], Mihaltan F [4, 11, 123], Milenkovic B [124-126], Molimard M [127], Montilla-Santana A [6, 30], Morais-Almeida M [128, 129], Morgan M [130], N'Diaye M [131], Nafti S [4, 132], Nekam K [4, 133], Neou A [134, 135], Nicod L [136], O'Hehir R [4, 137], Ohta K [4, 138], Paggiaro P [139], Palkonen S [3, 4, 140], Palmer S [141], Papadopoulos NG [4, 5, 63, 142], Papi A [9, 143], Passalacqua G [4, 47], Pavord I [144], Pigearias B [145], Plavec D [146], Postma DS [3, 147], Price D [4, 56, 197], Rabe KF [148], Radier Pontal F [2], Redon J [6, 149], Rennard S [150], Roberts J [151], Robine JM [2, 152], Roca J [14], Roche N [153], Rodenas F [6, 88], Roggeri A [154], Rolland C [155], Rosado-Pinto J [4, 7, 24, 57], Ryan D [4, 56, 156], Samolinski B [7, 110, 157], Sanchez-Borges M [158], Schünemann HJ [40, 41], Sheikh A [159], Shields M [160], Siafakas N [161], Sibille Y [162], Similowski T [192-195], Small I [163], Sola-Morales O [164], Sooronbaev T [4, 22, 57, 165], Stelmach R [166], Sterk PJ [27], Stiris T [167, 168], Sud P [169], Tellier V [170], To T [57], Triggiani M [6, 98, 200], Valenta R [4, 171], Valero AL [14], Valiulis A [4, 75, 76, 168, 199], Van Ganse E [172], Vandenplas O [4, 162], Vasankari T [91], Vestbo J [33, 173], Vezzani G [174], Viegi G [175], Visier L [1, 2, 8], Vogelmeier C [176], Vontetsianos T [177], Wagstaff R [178], Wahn U [135], Wallaert B [64, 179], Whalley B [97], Wickman M [3, 4, 109], Williams DM [180], Wilson N [181], Yawn BP [4, 182], Yiallourous PK [4, 183], Yorgancioglu A [4, 103], Yusuf OM [184], Zar HJ [185], Zhong N [186], Zidarn M [4, 187], Zuberbier T [134, 135]



PERSPECTIVE
INTEGRATED CARE PATHWAYS FOR AIRWAY DISEASES

Integrated care pathways for airway diseases (AIRWAYS-ICPs)

European Innovation Partnership on Active and Healthy Ageing, Action Plan B3
Mechanisms of the Development of Allergy (MeDALL, WP10)
GARD (Global Alliance against Chronic Respiratory Diseases, WHO) research demonstration project



European Innovation Partnership on Active and Healthy Ageing

Newsletter - **Issue 21** - April 2015

Content

- [- Conference on Innovative financing opportunities, 3rd June 2015](#)
- [- EIP on AHA in action](#)

- [- A Selection of News](#)
- [- Upcoming Events](#)

MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation

J. Bousquet^{1,2,3,243}, H. J. Schunemann⁴, J. Fonseca^{5,244,245,246}, B. Samolinski⁶, C. Bachert⁷, G. W. Canonica⁸, T. Casale⁹, A. A. Cruz^{10,247}, P. Demoly^{11,12,248}, P. Hellings¹³, A. Valiulis¹⁴, M. Wickman^{15,249}, T. Zuberbier^{16,250}, S. Bosnic-Anticevitch¹⁷, A. Bedbrook², K. C. Bergmann^{16,250}, D. Caimmi¹¹, R. Dahl¹⁸, W. J. Fokkens¹⁹, I. Grisle²⁰, K. Lodrup Carlsen^{21,251}, J. Mullol²², A. Muraro²³, S. Palkonen²⁴, N. Papadopoulos^{25,252}, G. Passalacqua⁸, D. Ryan^{26,253}, E. Valovirta²⁷, A. Yorgancioglu²⁸, W. Aberer²⁹, I. Agache³⁰, M. Adachi³¹, C. A. Akdis³², M. Akdis³², I. Annesi-Maesano^{12,248}, I. J. Ansotegui³³, J. M. Anto^{34,35,36,37}, S. Arnavielhe³⁸, H. Arshad³⁹, I. Baiardini⁸, A. K. Baigenzhin⁴⁰, C. Barbara⁴¹, E. D. Bateman⁴², B. Beghé⁴³, E. H. Bel⁴⁴, A. Ben Kheder⁴⁵, K. S. Bennoor⁴⁶, M. Benson⁴⁷, M. Bewick⁴⁸, T. Bieber⁴⁹, C. Bindeslev-Jensen¹⁸, L. Bjerner⁵⁰, H. Blain^{51,52}, A. L. Boner⁵³, L. P. Boulet⁵⁴, M. Bonini⁵⁵, S. Bonini⁵⁶, I. Bosse⁵⁷, R. Bourret⁵⁸, P. J. Bousquet^{12,248}, F. Braido⁸, A. H. Briggs⁵⁹, C. E. Brightling^{60,254}, J. Brozek⁴, R. Buhl⁶¹, P. G. Burney^{62,255,256}, A. Bush⁶³, F. Caballero-Fonseca⁶⁴, M. A. Calderon⁶⁵, P. A. M. Camargos⁶⁶, T. Camuzat^{67,257}, K. H. Carlsen⁶⁸, W. Carr⁶⁹, A. M. Cepeda Sarabia^{70,258}, N. H. Chavannes⁷¹, L. Chatzi⁷², Y. Z. Chen⁷³, R. Chiron⁷⁴, E. Chkhartishvili⁷⁴, A. G. Chuchalin^{75,259}, G. Ciprandi⁷⁶, I. Cirule⁷⁷, J. Correia de Sousa⁷⁸, L. Cox⁷⁹, G. Crooks⁸⁰, D. J. Costa^{2,11}, A. Custovic⁸¹, S. E. Dahlén⁸², U. Darsow^{83,260}, G. De Carlo²⁴, F. De Blay⁸⁴, T. Dedeu⁸⁵, D. Deleanu⁸⁶, J. A. Denburg⁸⁷, P. Devillier⁸⁸, A. Didier⁸⁹, A. T. Dinh-Xuan⁹⁰, D. Dokic⁹¹, H. Douagui⁹², G. Dray⁹³, R. Dubakiene⁹⁴, S. R. Durham⁹⁵, M. S. Dykewicz⁹⁶, Y. El-Gamal⁹⁷, R. Emuzyte⁹⁸, A. Fink Wagner⁹⁹, M. Fletcher¹⁰⁰, A. Flocchi¹⁰¹, F. Forastiere¹⁰², A. Gamkrelidze¹⁰³, B. Gemiciglu¹⁰⁴, J. E. Gereda¹⁰⁵, S. González Díaz¹⁰⁶, M. Gotua¹⁰⁷, L. Grouse¹⁰⁸, M. A. Guzmán¹⁰⁹, T. Haahela¹¹⁰, B. Hellquist-Dahl¹¹¹, J. Heinrich¹¹², F. Horak¹¹³, J. O. B. Hourihane¹¹⁴, P. Howarth¹¹⁵, M. Humbert^{116,261}, M. E. Hyland¹¹⁷, J. C. Ivancevich¹¹⁸, E. J. Jares¹¹⁹, S. L. Johnston^{120,262}, G. Joos¹²¹, O. Jonquet¹²², K. S. Jung¹²³, J. Just^{124,263}, I. Kaidashev¹²⁵, O. Kalayci¹²⁶, A. F. Kalyoncu¹²⁷, T. Keil^{128,264}, P. K. Keith¹²⁹, N. Khaltaev¹³⁰, L. Klimek¹³¹, B. Koffi N'Goran¹³², V. Kolek¹³³, G. H. Koppelman¹³⁴, M. L. Kowalski¹³⁵, I. Kull¹³⁶, P. Kuna¹³⁷, V. Kvedariene¹³⁸, B. Lambrecht¹³⁹, S. Lau¹⁴⁰, D. Larenas-Linnemann¹⁴⁰, D. Laune¹⁴¹, L. T. T. Le¹⁴¹, P. Lieberman¹⁴², B. Lipworth¹⁴³, J. Li¹⁴⁴, R. Louis¹⁴⁵, Y. Magard¹⁴⁶, A. Magnan¹⁴⁷, B. Mahboub¹⁴⁸, I. Majer¹⁴⁹, M. J. Makela¹¹⁰, P. Manning¹⁵⁰, E. De Manuel Keenoy¹⁵¹, G. D. Marshall¹⁵², M. R. Masjedi¹⁵³, M. Maurer¹⁵⁴, S. Mavale-Manuel¹⁵⁵, E. Melén¹⁵⁶, E. Melo-Gomes⁴¹, E. O. Meltzer¹⁵⁷, H. Merk¹⁵⁸, N. Miculinic¹⁵⁹, F. Mihaltan¹⁶⁰, B. Milenkovic^{161,265}, Y. Mohammad¹⁶², M. Molimard¹⁶³, I. Momas^{164,165}, A. Montilla-Santana¹⁶⁶, M. Morais-Almeida¹⁶⁷, R. Mösges¹⁶⁸, L. Namazova-Baranova¹⁶⁹, R. Naclerio¹⁷⁰, A. Neou^{16,250}, H. Neffen¹⁷¹, K. Nekam¹⁷², B. Niggemann¹⁷³, T. D. Nyembue¹⁷⁴, R. E. O'Hehir^{175,266}, K. Ohta¹⁷⁶, Y. Okamoto¹⁷⁷, K. Okubo¹⁷⁸, S. Ouedraogo¹⁷⁹, P. Paggiaro¹⁸⁰, I. Pali-Schöll^{181,267}, S. Palmer²⁷⁵, P. Panzner¹⁸², A. Papi¹⁸³, H. S. Park¹⁸⁴, I. Pavord¹⁸⁵, R. Pawankar¹⁸⁶, O. Pfaar^{187,268}, R. Picard¹⁸⁸, B. Pigearias¹³², I. Pin¹⁸⁹, D. Plavec¹⁹⁰, W. Pohl¹⁹¹, T. A. Popov¹⁹², F. Portejoie², D. Postma¹⁹³, P. Potter¹⁹⁴, D. Price^{195,269}, K. F. Rabe^{196,270}, F. Raciborski⁶, F. Radier Pontal¹⁹⁷, S. Repka-Ramirez¹⁹⁸, C. Robalo-Cordeiro¹⁹⁹, C. Rolland²⁰⁰, J. Rosado-Pinto²⁰¹, S. Reitamo¹¹⁰, F. Rodenas²⁰², M. Roman Rodriguez²⁰³, A. Romano²⁰⁴, N. Rosario²⁰⁵, L. Rosenwasser²⁰⁶, M. Rottem²⁰⁷, M. Sanchez-Borges^{208,271}, G. K. Scadding²⁰⁹, E. Serrano²¹⁰, P. Schmid-Grendelmeier²¹¹, A. Sheikh²¹², F. E. R. Simons²¹³, J. C. Sisul²¹⁴, I. Skrinde²¹⁵, H. A. Smit²¹⁵, D. Solé²¹⁶, T. Sooronbaev²¹⁷, O. Spranger⁹⁹, R. Stelmach²¹⁸, T. Strandberg²¹⁹, J. Sunyer²²⁰, C. Thijs²²⁰, A. Todo-Bom²²¹, M. Triggiani²²², R. Valenta²²³, A. L. Valero²²⁴, M. van Hage²²⁵, O. Vandenplas²²⁶, G. Vezzani^{227,272}, P. Vichyanond²²⁸, G. Viegi^{229,273}, M. Wagenmann²³⁰, S. Walker²³¹, D. Y. Wang²³², U. Wahn¹⁷³, D. M. Williams²³³, J. Wright²³⁴, B. P. Yawn²³⁵, P. K. Yiallourou^{236,274}, O. M. Yusuf²³⁷, H. J. Zar²³⁸, M. E. Zernotti²³⁹, L. Zhang²⁴⁰, N. Zhong¹⁴⁴, M. Zidarn²⁴¹ & J. Mercier²⁴²



MASK funding



European
Commission

REGIONAL POLICY

InfoRegio

European Commission > Regional Policy > Funding > European Regional Development Fund



Policy

Funding

What's new


In your country

European Regional Development Fund

The ERDF aims to strengthen economic and social cohesion in the European Union by correcting imbalances between its regions.

The ERDF focuses its investments on several key priority areas. This is known as 'thematic concentration':

- Innovation and research;
- The digital agenda;
- Support for small and medium-sized enterprises (SMEs);



Patient with allergic rhinitis symptoms

Self-management

Answer the questions below

Are you currently taking medication for your allergic rhinitis?

Have you ever taken medication for your allergic rhinitis?

Overall how much are your allergic symptoms bothering you today?

Not at all bothersome Extremely bothersome

To answer this question use your finger to touch the line and indicate how much your allergic symptoms are bothering you today. Once you have touched the line a mark (blue line) will appear to show your response. If the mark on the line isn't exactly where you want it to be you can move it with your finger.

Menu My symptoms

Overall how much are your allergic symptoms bothering you today?

Not at all bothersome Extremely bothersome

Primary

Management

Specialist

Answer the questions below

Are you currently taking medication for your allergic rhinitis?


Have you ever taken medication for your allergic rhinitis?

Overall how much are your allergic symptoms bothering you today?

Not at all bothersome Extremely bothersome


To answer this question use your finger to touch the line and indicate how much your allergic symptoms are bothering you today. Once you have touched the line a mark (blue line) will appear to show your response. If the mark on the line isn't exactly where you want it to be you can move it with your finger.

Emergency care (asthma)



Server push: data page load
Show patient data

'Close Viewer' button pressed
Return to QR page



Select
'Show data on PC'



Scan started

Stop scan



Scan successful



Allergy Diary by MACVIA-ARIA

Your health is in your hands

*Take control of your
allergic rhinitis (hay fever)
Don't let it control you*



Available from Google Play
and Apple store
Free to download



The Allergy Diary by MACVIA-ARIA enables you to keep a daily record of your allergic rhinitis (also known as hay fever) and asthma symptoms as well as your medication use. The app is simple to use, and combines practicality with good scientific practice, having been developed with a global team of world leading allergy clinicians. The symptom ratings you provide daily are captured using validated measures that can be interpreted as a level of symptom control. These are simple rating scales that just require you to tap a line to indicate your response to three or four (if you have asthma) symptom questions. You can also record the medication you take each day.



Better understand your daily allergic symptoms



Regularly monitor your allergy



Personalize your treatment with your health care provider



Optimize and anticipate your next season treatment

All collected data are kept secure.

The Allergy Diary app is available in the following countries:
Austria, Belgium, Denmark, Finland, France, Germany,
Greece, Italy, Lithuania, Netherlands, Poland, Portugal,
Spain, Sweden, UK



MACVIA*LR



Regular use of the App allows you to better understand your symptoms, optimize your treatment and anticipate your allergic reactions

Originator and adopter organisations

Originator

MACVIA-France

Adopters

1. Aragon
2. Campania
3. Catalonia
4. City of Helsinki
5. Ageing@Coimbra
6. Heraklion
7. Cologne-Bonn Health Region
8. Life Tech Valley
9. Liguria
10. Lodz
11. Medical Delta
12. Milan Metropolitan - Bergamo Province
13. NHS 24
14. Northern Ireland
15. Olomouc
16. Pays de la Loire
17. Porto4Age
18. Puglia
19. Regione Piemonte
20. Region of Southern Denmark
21. Région Nouvelle Aquitaine
22. Turkey (Global Alliance Chronic Respiratory Diseases Regional Network)
23. ARIA Sweden
24. ARIA Lithuania



The European Innovation Partnership
on Active and Healthy Ageing



European scaling-up

Strategy

in **Active &
Healthy Ageing**